Protective effect of thymosin alpha-1 on postnatal systemic inflammation induced learning and memory impairment in mice
Ge Wang, Wenfu Yu, Xiao Wang, Fen He, Juntao Zou
Abstract
Ge Wang, Wenfu Yu, Xiao Wang, Fen He, Juntao Zou
Abstract
Objective To explore the effect of thymosin alpha-1 (Ta1) on postnatal systemic inflammation-induced learning and memory impairment in mice and their relevant mechanism. Methods (1) Twenty-four neonatal C57BL/6 mice were randomly assigned into normal saline group,lipopolysaccharide (LPS, 0.3 mg/kg) group, LPS (0.6 mg/kg) group, and LPS (0.9 mg/kg) group. And the animals were intraperitoneally injected with different doses of LPS or equal volume of saline for 5 days. The variations of body weight, liver weight relative to the body and tumor necrosis factor-α (TNF-α) level in serum and brain tissues were observed to determine the appropriate dose of LPS for simulating neonatal clinical infection. (2) A total of 60 newborn mice were randomly divided into three groups: control group, LPS group and Ta1 treatment group; mice in each group were continuously injected with equal volume saline, LPS (0.6 mg/kg) and Ta1 (0.4 mg/kg)+LPS (0.6 mg/kg) for 5 days. On day 28 and on day 56, Morris water maze was used to measure the spatial learning and memory abilities of mice; the concentrations of TNF-α, interleukin-1β (IL-1β), brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in the hippocampus were examined by ELISA, and the expressions of toll-like receptor 4 (TLR4) and nuclear factor-κB (NF-κB) were measured by Western blotting. Results (1) As compared with the normal saline group, the mice in the LPS group (0.6 mg/kg) had significantly slower growth ([2.23±0.22] g vs. [1.18±0.21] g), increased relative liver weight to the body (0.052±0.004 vs. 0.072±0.007) and increased TNF-α levels in serum and brain tissues ([62.01±3.32] pg/mL vs. [151.06±14.51] pg/mL; [186.03±13.24] pg/mL vs. [298.71±41.61] pg/mL, P<0.05). (2) As compared with the LPS group, Ta1 treatment group had significantly shortened average escape latency in place navigation test, prolonged active time in spatial probe test, statistically decreased hippocampal TNF-α, IL-1β, TLR4 and NF-κB levels ([73.32±5.18] pg/mL vs. [58.61±4.03] pg/mL; [99.15±8.30] pg/mL vs. [75.56±6.13] pg/mL; 2.32±0.29 vs. 1.71±0.26; 1.77±0.24 vs. 1.26±0.14) and significantly increased BDNF and NGF levels ([1.33±0.12] pg/mL vs. [1.69±0.25] pg/mL; [41.45±3.47] pg/mL vs. [50.38±5.02] pg/mL, P<0.05). Conclusion Ta1 improves learning and memory functions and alleviates neuro-inflammation in postnatal infection of mice, and the underlying mechanism probably involves in inhibiting TLR4/NF-κB signaling pathway activation and increasing neurotrophic factors. Key words: Infectious disease; Thymosin alpha-1; Learning and memory ability; Brain-derived neurotrophic factor; Nerve growth factor; Toll-like receptor 4; Nuclear factor-κB
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To explore the effect of thymosin alpha-1 (Ta1) on postnatal systemic inflammation-induced learning and memory impairment in mice and their relevant mechanism. Methods (1) Twenty-four neonatal C57BL/6 mice were randomly assigned into normal saline group,lipopolysaccharide (LPS, 0.3 mg/kg) group, LPS (0.6 mg/kg) group, and LPS (0.9 mg/kg) group. And the animals were intraperitoneally injected with different doses of LPS or equal volume of saline for 5 days. The variations of body weight, liver weight relative to the body and tumor necrosis factor-α (TNF-α) level in serum and brain tissues were observed to determine the appropriate dose of LPS for simulating neonatal clinical infection. (2) A total of 60 newborn mice were randomly divided into three groups: control group, LPS group and Ta1 treatment group; mice in each group were continuously injected with equal volume saline, LPS (0.6 mg/kg) and Ta1 (0.4 mg/kg)+LPS (0.6 mg/kg) for 5 days. On day 28 and on day 56, Morris water maze was used to measure the spatial learning and memory abilities of mice; the concentrations of TNF-α, interleukin-1β (IL-1β), brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in the hippocampus were examined by ELISA, and the expressions of toll-like receptor 4 (TLR4) and nuclear factor-κB (NF-κB) were measured by Western blotting. Results (1) As compared with the normal saline group, the mice in the LPS group (0.6 mg/kg) had significantly slower growth ([2.23±0.22] g vs. [1.18±0.21] g), increased relative liver weight to the body (0.052±0.004 vs. 0.072±0.007) and increased TNF-α levels in serum and brain tissues ([62.01±3.32] pg/mL vs. [151.06±14.51] pg/mL; [186.03±13.24] pg/mL vs. [298.71±41.61] pg/mL, P<0.05). (2) As compared with the LPS group, Ta1 treatment group had significantly shortened average escape latency in place navigation test, prolonged active time in spatial probe test, statistically decreased hippocampal TNF-α, IL-1β, TLR4 and NF-κB levels ([73.32±5.18] pg/mL vs. [58.61±4.03] pg/mL; [99.15±8.30] pg/mL vs. [75.56±6.13] pg/mL; 2.32±0.29 vs. 1.71±0.26; 1.77±0.24 vs. 1.26±0.14) and significantly increased BDNF and NGF levels ([1.33±0.12] pg/mL vs. [1.69±0.25] pg/mL; [41.45±3.47] pg/mL vs. [50.38±5.02] pg/mL, P<0.05). Conclusion Ta1 improves learning and memory functions and alleviates neuro-inflammation in postnatal infection of mice, and the underlying mechanism probably involves in inhibiting TLR4/NF-κB signaling pathway activation and increasing neurotrophic factors. Key words: Infectious disease; Thymosin alpha-1; Learning and memory ability; Brain-derived neurotrophic factor; Nerve growth factor; Toll-like receptor 4; Nuclear factor-κB
Key concepts: Endocrinology, Saline, Internal medicine, Lipopolysaccharide, Tumor necrosis factor alpha, Hippocampus, TLR4, Medicine